Virus-host interactions : entry and replication of Crimean-Congo hemorrhagic fever virus by Andersson, Cecilia
From DEPARTMENT OF MICROBIOLOGY,  
TUMOR AND CELL BIOLOGY 
Karolinska Institutet, Stockholm, Sweden 
VIRUS-HOST INTERACTIONS: 
ENTRY AND REPLICATION OF 
CRIMEAN-CONGO  
HEMORRHAGIC FEVER VIRUS 
Cecilia Andersson 
 
Stockholm 2013 
 
 All previously published papers were reproduced with permission from the publisher. 
Published by Karolinska Institutet. 
Printed by Åtta.45 tryckeri AB 
© Cecilia Andersson, 2013 
ISBN 978-91-7549-533-0 
 
  
i 
Virus-Host interactions: Entry and replication of  
Crimean-Congo hemorrhagic fever virus 
 
 
AKADEMISK AVHANDLING 
som för avläggande av medicine doktorsexamen (Ph.D.) vid 
Karolinska Institutet offentligen försvaras i förläsningsalen Jacob 
Berzelius, Berzelius väg 3, Solna 
 
Fredagen den 16 maj 2014, kl 9:30 
av 
Cecilia Andersson 
Huvudhandledare: 
Docent Ali Mirazimi 
Karolinska Institutet 
Institutionen för mikrobiologi,  
tumör- och cellbiologi 
 
Bihandledare: 
Professor Mats Nilsson 
Stockholms universitet 
Institutionen för biokemi och  
biofysik 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fakultetsopponent: 
Dr. Pierre-Yves Lozach 
Heidelberg University 
Department of Infectious Diseases 
 
Betygsnämnd: 
Professor Michael Lindberg 
Linnéuniversitetet 
Institutionen för kemi och biomedicin 
 
Professor Francesca Chiodi 
Karolinska Institutet 
Institutionen för mikrobiologi,  
tumör- och cellbiologi 
 
Docent Marianne Jansson 
Lunds universitet 
Avdelningen för medicinsk  
mikrobiologi 
  
ii 
 
 
 
 
 
 
 
 
  
iii 
 
“When I was 5years old, my mother always told me 
that happiness was the key to life. When I went to school, they 
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ABSTRACT 
Crimean-Congo hemorrhagic fever (CCHF) is a severe acute human disease with 
potential lethal outcome caused by a virus, Crimean-Congo hemorrhagic fever 
virus (CCHFV). Not much is known regarding how CCHFV infects cells, 
replicates and why it cause vascular dysfunction. To better understand CCHFV-
pathogenesis increased knowledge regarding these issues is needed. 
Viruses have to enter a host cell in order to replicate its genome and here we 
show that CCHFV entry occur by clathrin-mediated endocytosis and is pH-
dependent. 
A new in situ detection technique was establihed to visualize individual CCHFV 
cRNA and vRNA transcripts. Potential colocalization with the viral nucleocapsid 
protein (NP) was also investigated. cRNA was found to be more concentrated to 
particular regions within the cytoplasm and co-localized with CCHFV NP. While 
vRNA was detected throughout the cytoplasma not colocalizating with CCHFV 
NP.   
It is not known if the vascular leakage observed in CCHF is due to direct virus 
infection or is immune-mediated. A new in vitro model system was therefore 
established and it was found that CCHFV has a preference for basolateral entry. 
However and surprisingly, using CCHFV-infected monocyte-derived dendritic 
cells (moDCs) or their supernatant, a preference for apical entry was observed. 
This indicate that the change in entry site could be due to soluble factors from 
the moDCs. Neither direct infection nor addition of CCHFV-infected moDCs 
affected the cellular permeability of the human polarized epithelial cell layer, 
indicating that other factors are most likely are causing the vascular leakage.  
Taken together, we established several new in vitro model systems to study 
CCHFV’s interaction with host cells. We also demonstrated the entry pathway for 
CCHFV into cells. These data and tools will hopefully facilitate and promote 
research on virus-host interactions which in turn may result in the development of 
new antivirals and/or vaccines against CCHFV. 
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1 INTRODUCTION 
Crimean-Congo hemorrhagic fever (CCHF) is exclusively a human disease with 
a high case fatality rate, of up to 30%. The virus causing the disease, Crimean-
Congo hemorrhagic fever virus (CCHFV), is spread by ticks and humans 
contract the virus following tick bites, the handling of infected livestock or 
caring for a patient in the acute phase of the disease. There is currently no 
commercially available vaccine and no specific treatment. 
 
1.1 HISTORY 
A human disease with bleeding from numerous sites and where the causing agent 
was believed to be a small tough tick or louse was first described in 1100 ad [1]. 
A similar disease has also been known in the Termez region of Uzbekistan under 
3 names indicating blood taking, nose bleeding and black death [1]. But the first 
clinical description of CCHF was made during an outbreak in Crimea in 1944, 
when over 200 military personnel developed severe disease with bleeding from 
various sites while helping restore abandoned farmland [1]. The following years 
there were other outbreaks of what was then referred to as Crimean hemorrhagic 
fever in other parts of Eastern Europe [2]. The viral nature of the disease was 
determined by Chumakov, who gave serum from hemorrhagic patients to 
psychiatric patients. He also determined ticks as the vector by giving a solution 
of crushed Hyalomma ticks to healthy volunteers and in both studies disease was 
manifested [1]. 
In 1969, the Soviet reference strain for Crimean hemorrhagic fever was found to 
be antigenically identical to several strains isolated in Congo where it was known 
to cause a similar disease [3]. After some dispute over the name, Crimean-Congo 
hemorrhagic fever was finally accepted [1].  
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2 CCHF-VIRUS 
CCHFV belongs to the Bunyaviridae family and is classified within the 
Nairovirus genus. The Bunyaviridae family is a large family containing more 
than 350 viruses divided into 5 genera, Orthobunyavirus, Nairovirus, 
Phlebovirus, Hantavirus and Tospovirus [4]. With the exception of 
Tospoviruses all other members are transmitted by animals, rodents for 
Hantavirus and arthropods (mosquitos, tick or sandfly) for the others. 
Bunyaviridae viruses are enveloped and circular. All members have a genome 
consisting of 3 single stranded RNA segments of negative sense, the large (L), 
medium (M) and the small (S) segment, encoding 4 structural proteins [5], 
several members also encode nonstructural proteins.  
Nairoviruses are spread by ticks and have a very large L segment compared to 
other Bunyaviridae members, nearly twice the size [6]. The genus consists of 35 
viruses, but only 5 viruses are known to cause human disease. Apart from 
CCHFV, Farallon and Erve virus may cause human disease with headache, fever 
and neurological disorder while Dugbe and Nairo sheep disease virus can cause 
human disease but mainly cause disease in sheep and goats [7]. 
 
2.1 MOLECULAR CHARACTERISTICS  
The CCHF virus particle is spherical and between 90-100nm in diameter [8, 9]. 
It has an outer cell-derived lipid envelope membrane, through which the 
glycoproteins, Gn and Gc, protrude. Like the other Bunyaviridae members, 
CCHFV has a negative single strand genome divided on three segments, the 
large (L), medium (M) and small (S). Together with the nucleocapsid protein 
(NP) each genome strand form individual ribonucleocapsids [5, 10]. Each viral 
particle also contains RNA-dependent RNA polymerase (RdRp), necessary to  
initiate transcription and genome replication. 
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Figure 1: Schematic representation of CCHFV 
The terminal sequences on each strand is complementary and conserved in all 
Nairoviruses [11, 12]. From other Bunyaviridae it is predicted that the terminal 
sequences bind to each other forming stable panhandle structures making the 
genome segments into closed circular RNA molecules [13]. It has been 
suggested that the terminal base-pairing provide the functional promoter region 
for the viral polymerase [12]. CCHFV’s genome, encodes 4 structural proteins. 
The S-segment encodes the NP, which coats and protects the genome from 
degradation. It has a large globular domain that can bind RNA and a protruding 
arm, with a caspase-3 cleavage site [14, 15]. Structural alignment with other 
RNA virus NPs showed it to be most similar to Lassa virus (Arenaviridae) [15]. 
The M-segment encodes a polyprotein, that through complex post-translational 
cleavage by several proteases produce the two transmembrane glycoproteins, Gn 
and Gc, named in accordance with their relative proximity to the respective ends 
of the polyprotein. The mRNA is first cleaved to preGn and preGc in the ER and 
are then transported to the Golgi, where they are further cleaved, glycosylated, 
folded and integrated into virions [16, 17]. Gn has a chaperone-like function for 
Gc and must be present for correct folding and transportation to the Golgi 
complex to occur [18, 19], while Gc has been suggested to be more important 
during infection [19]. A nonstructural protein [20] as well as three other 
domains, GP38, GP85 and GP160 with unknown functions has also been 
detected on the polyprotein [17]. The L-segment encodes the viral polymerase, 
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RdRp, necessary for viral replication and mRNA synthesis. It has an ovarian 
tumor protease domain near its N-terminus that has been shown to remove 
ubiquitin from cellular proteins [21].   
 
2.2 REPLICATION 
 
Figure 2: Schematic representation of CCHFV’s replication 
 
The two glycoproteins, Gn and Gc, are believed to determine cell and tissue 
tropism and the ability of the viruses to infect susceptible cells via recognition 
and binding of one or more cellular receptors. Neutralizing antibodies towards 
both glycoproteins are produced during infection, but in vitro and in vivo studies 
showed that only antibodies towards Gc protected both cells and mice from 
infection [19, 22]. The exact receptor for CCHFV is not known, but one study 
using the ectodomain of Gn and Gc found nucleolin to be important for entry 
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[23]. Following attachment, CCHFV enters through clathrin-mediated 
endocytosis (CME) in a pH-dependent manner with fusion likely to occur in the 
early endosomes [24, Paper I]. Viral replication occurs in the cytoplasm where 
the negative stranded genome interacts with the viral RdRp for the synthesis of 
the positive stranded messaganger RNA (mRNA) and full-length 
complementary RNA (cRNA). The mRNA is used for transcription of the viral 
proteins and the cRNA is used as template for the synthesis of new genomic viral 
RNA (vRNA). Newly synthesized vRNA binds to the NP and is then 
incorporated with the glycoproteins in the Golgi complex (Donets Chumakov 
1977), after which the virus is released by exocytosis. Host-cell microtubule are 
needed during replication, assembly and egress [25] while actin is important for 
transporting NP to the site of assembly [26]. 
 
2.3 OCCURRENCE 
The occurrence of CCHFV closely coincides with that of its vector, ticks 
primarily of the Hyalomma species [1, 27, 28]. It can be found in western, central 
and southern Africa, the Balkans, the Middle East, southern Russia and south- 
western Asia [1, 27, 29].  
          
 
Figure 3: Occurrence of CCHFV, reprinted with permission from CDC 
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In Europe it is mainly found in the Balkans, Russia and countries of the former 
Soviet Union. Previously there had only been two antibody based reports of 
CCHFV from Western Europe, both on bats, one from the border of France and 
Spain and one from Portugal [1, 30]. But a recent report found CCHFV positive 
ticks in Spain [31]. Another recent report found CCHFV positive ticks on a 
migratory bird travelling from Africa to southern Europe [32]. Imported cases of 
human CCHF have occurred to France [33] and the United Kingdom [34], but 
without further transmission. During the last few year most cases of CCHF have 
been reported from Turkey. Although the virus was known to circulate there 
before, the first clinical cases of CCHF in Turkey didn’t occur until 2002 [35]. 
However, since then numerous cases have been confirmed, between 2002 and 
2012, 6864 cases were reported [36]. 
The increase in cases is most likely a combination of better awareness within the 
health care system, effective molecular methods for virus detection and virus 
spread. The spread can both be explained by natural bird migration, where birds 
are carrying infected ticks [32], and by the trade of virus infected and/or tick-
infested livestock to previously unaffected areas where permissive ticks are 
available [1, 37, 38]. The number of human cases also increase when previously 
abandoned farm land is recultivated in areas where the virus is already 
circulating [2]. 
 
2.4 TRANSMISSION 
CCHFV is spread and maintained by ticks. Human are exposed to the virus 
following tick bites, the handling of viremic or tick-infected livestock or through 
person-to-person (nosocomial) transmission. Humans who are mainly at risk of 
contracting the virus therefore include agricultural and slaughterhouse workers 
as well as hospital staff caring for infected patients. 
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Figure 4: Schematic depiction of the different transmission routes for CCHFV. 
Reprinted with permission from Elsevier. 
 
Ticks 
The virus circulates unnoticed in nature in a tick–vertebrate-tick cycle where 
humans are accidental hosts. The role of ticks in the maintenance of the virus 
has been well established both through field studies and experimental 
assessments of vector competence in the laboratory, and while some 
Nairoviruses infect argasid (soft) ticks, CCHFV are maintained exclusively in 
ixodid (hard) ticks [1, 6, 39]. The primary vector and reservoir for CCHFV is 
ticks of the Hyalomma species, particular H. marginatum, and the ticks can 
remain infected throughout their several year life-time [6]. The virus can be 
maintained in the tick through all its life stages from egg via larvae and nymph 
to adult (transstadial transmission), as well as being spread from male to female 
(venereal transmission) and mother to egg (transovarial transmission) [6, 40, 41]. 
Additionally, CCHFV has been shown to spread by “non-viremic” transmission 
so called cofeeding, when virus present in one ticks saliva is spread directly to 
nearby feeding ticks without causing viremia in the animal that they feed on [42, 
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43]. Hyalomma ticks are generally 2-host ticks where the first host usually is 
ground-feeding birds or small mammals such as hares or hedgehogs, while the 
second host is a larger animal such as sheep or cattle [1]. Some tick species wait 
passively to encounter a vertebrate (“ambush ticks”), but Hyalomma ticks are 
“hunting” ticks, which can quest up to 400m to find their hosts [6]. 
Wild and domestic animals 
Most mammals appear to be susceptible to infection with CCHFV, but only a 
few develop a sufficiently high viremia to efficiently infect ticks [44]. But in 
some vertebrates the bite of an infected tick causes viral replication and viremia, 
providing a source of infection for additional ticks as well as the risk of spreading 
the virus to humans. Experimental infections of wild and domestic animals have 
found that sheep, calves, scrub hares and ostriches develop a short viremia and 
in some cases were able to transmit the virus to feeding ticks [6, 45]. Because 
most vertebrates infected with CCHFV develop only a transient viremia without 
apparent illness, the identification of animal hosts of CCHFV has largely been 
done on the detection of virus-specific antibodies in collected serum from 
livestock or occasionally wild animals. The occurrence of antibody positive 
livestock has been found to correlate with the occurrence of human cases [6]. 
Even though birds can carry a large number of virus infected ticks, most birds 
appear to be refractory to the virus [45, 46]. 
Nosocomial transmission 
The virus has been shown to spread from person-to person and a number of 
nosocomial cases have been reported where hospital staff, laboratory personnel 
and/or relatives have contracted the virus from a CCHFV infected patient [1, 47-
50]. Fortunately, increased information regarding protective nursing has reduced 
the number of nosocomial cases and showed that standard barrier nursing 
methods are efficient to prevent further transmission of CCHFV [47, 50, 51].   
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3 CCHF- THE DISEASE 
CCHFV infection is only known to cause disease in humans. It has been 
calculated that approximately 1 out of 5 persons exposed to CCHFV develop 
symptoms [52, 53]. Although the duration and symptoms vary among affected 
individuals, most patients only develop a mild or subclinical infection. Some 
patients do however, progress into the more severe symptoms.  
The disease is divided into 4 phases: incubation, prehemorrhagic, hemorrhagic 
and convalesce [1]. The incubation time can vary from a few days up to a week 
and has been suggested to differ depending on transmission route, with shorter 
incubation times for tick bite or livestock handling compared to nosocomial [54]. 
Viral load has also been suggested to affect incubation time [29]. 
Following incubation, the patients enter the prehemorrhagic phase. This is 
characterized by a rapid onset of fever, headache, myalgia, nausea and vomiting 
[1, 49, 54] which usually last approximately 3 days after which some patients 
enter the hemorrhagic phase. The hemorrhagic phase is characterized by 
bleeding, ranging from dermal petechiae to gastrointestinal hemorrhage [29, 49, 
54, 55]. The most common bleeding sites includes the nose, gastrointestinal 
system, urinary tract and the respiratory tract [56]. Other symptoms include 
enlarged liver and spleen, elevated liver enzymes, prolonged bleeding times and 
in severe cases disseminated intravascular coagulation (DIC) [1, 29, 54]. The 
severity of the disease has been correlated to high viral load and low antibody 
response [55, 57-61]. Other severity markers include thrombocytopenia, 
leucopenia, elevated liver enzymes, prolonged bleeding times and bleeding [55, 
60, 62, 63]. Death usually occur between days 6-10 after disease onset and is due 
to multiple organ failure caused by severe anemia, dehydration and shock [60]. 
For patients that recover, the convalescence can be long and include symptoms 
like weakness, labile pulse and confusion, all of which are temporary [1, 54]. 
There have not been any reports of relapse of the infection [29]. 
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3.1 TREATMENT 
Most human CCHFV-infections appear to be asymptomatic or only cause a mild 
febrile illness [6, 53, 64]. But patients that develop the severe form of the disease 
require extensive hospital stay with special care and protective nursing in order 
to limit the spread of the disease. As there currently is no commercial vaccine or 
specific treatment available, patients are usually given a combination of 
supportive treatments. This includes giving volume replacement, to treat the fall 
in blood pressure and diminishing organ perfusion, giving fresh frozen plasma 
and platelets for the coagulation abnormalities as well as blood transfusions for 
significant hemorrhage [6].  
It has been suggested that the different phases of the disease should be treated 
differently with an antiviral such as ribavirin, given during the first clinical phase 
when viremia and virus replication is high and drugs targeted at DIC or sepsis 
during the second phase when the viral load declines and patients enter the 
hemorrhagic phase [65]. In line with this a recent study found corticosteroids to 
be effective, particularly for patients with severe CCHF [62].  
Studies of the efficiency of giving immunoglobulin is lacking, although 
immunoglobulin derived from plasma of CCHF survivor donors is used as 
treatment in Bulgaria [66, 67] and was recently used in Turkey [68]. But no case-
control studies have been published on the efficiency in CCHF patients [69].  
Ribavirin 
Ribavirin (Virazole®) is a synthetic guanosine analogue that is used to treat a 
number of RNA and DNA viral infections. Its full mechanism is not yet known, 
although both indirect and direct functions have been proposed to explain its 
antiviral activity [70]. Most clinical comparative CCHF studies has found that 
ribavirin is beneficial, as long as it is initiated early in the course of the disease 
[62, 65]. However only one randomized clinical trial has been conducted and 
they found no significant difference with regard to disease outcome [71].  
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Vaccines 
There is no FDA approved vaccine for CCHFV. A vaccine against CCHFV using 
formaldehyde-inactivated mouse brain tissue was developed in the Soviet Union 
in the early 1970ies [69] and a similar vaccine is still being used in Bulgaria and 
given to soldiers, medical personnel and other high risk groups in endemic areas 
[72]. However, no case-controlled studies of its efficiency has been conducted 
and a recent study found that the Bulgarian vaccine only elicited a low 
neutralizing antibody response, even in persons that had received it 4 times [73]. 
Two studies where vaccination with CCHFV Gn and Gc either delivered as a 
DNA vaccine [74] or as purified proteins from transgenic plants [75], induced 
neutralizing antibodies in mice. Yet, at the time there was no animal model 
available for CCHF and so the actual response could not be assessed in a 
challenge model. However, a promising new CCHFV vaccine candidate based 
on a poxvirus vector expressing the CCHFV glycoproteins, was found to elicit 
both a cellular and humoral response and protect mice challenged with CCHFV 
[76]. But whether this could be used as a human vaccine against CCHFV remains 
to be investigated. 
 
3.2 ANIMAL MODELS  
CCHF symptoms has so far only been reported in humans and this in 
combination with the requirement for BSL-4 containment, has made it difficult 
to develop an animal model to study CCHF pathogenesis. Attempts to study the 
disease in adult mice, rats, hamsters, guinea pigs, rabbits, sheep, calves, donkeys 
and non-human primates have all proven unsuccessful [1, 6]. Although a short 
viremia could be detected in several animals this was not sufficient to cause 
CCHF symptoms [6]. The virus does however replicate to high titers in newborn 
mice [77, 78], but as they have an immature immune response they are not a 
good model to study the pathogenesis of the disease.  But recently, two different 
knock-out mice models were presented which revealed the importance of the 
IFN type I response in controlling the disease. The mice lacked either the cell-
surface IFN- αβ receptor [79] or the intracellular signal transducer and activator 
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of transcription (STAT)-1 protein [80] and developed CCHF symptoms 
following infection. Hopefully, the introduction of these new animal models can 
provide more knowledge regarding CCHF’s pathogenesis. 
 
3.3 PATHOLOGY 
Due to the safety regulations and the sporadic occurrence of the disease, there 
are only a few reported necropsies on CCHF patients [57, 81, 82]. Further 
information comes the new animal models [79, 80]. The main finding from 
human necropsies included necrosis of the liver, which varied in extent but 
generally existed in multiple foci associated with viral antigen and no 
inflammatory infiltrates [54, 57, 81, 82]. The liver dysfunction is also reflected 
by the elevated liver enzymes detected during CCHF which can be used as a 
prognostic marker [56, 60, 63]. Damage to the spleen was also noted with 
marked lymphocyte depletion as well as hemorrhage and infection of endothelial 
cells of other organs [57, 81, 82]. The two new animal models developed similar 
symptoms with necrosis of the liver as well as prominent lymphocyte depletion 
and debris in the spleen, consistent with lymphocyte apoptosis, and 
gastrointestinal bleeding [80, 83].  
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4 IMMUNE RESPONSES TOWARDS CCHFV 
INFECTION 
The host response is made up of the innate and adaptive immune systems, which 
usually act together in synergy. With the innate response representing the first 
line of defense and the adaptive becoming prominent after several days as 
antigen-specific T and B cells have undergone clonal expansion. They support 
each other with components of the innate immune system contributing to the 
activation of the antigen-specific cells and the antigen-specific cells amplifying 
the innate response [84].  
 
4.1 INNATE IMMUNE SYSTEM 
The innate immune system broadly includes all aspects encoded in their mature 
form by the germline genes of the host, this includes physical barriers like 
epithelial cell layers that express tight cell-cell contacts, soluble proteins as well 
as membrane-bound receptors and proteins that binds to the surface of invading  
microbes [84]. 
 
Interferons 
Interferons (IFNs) are a group of secreted cytokines that have antiviral effects. 
They recognize viruses through toll-like receptors or pathogen recognition 
receptors. There are 3 different types, type I, II and III. In vitro studies has shown 
that CCHFV is sensitive to type I IFNs and several of its antiviral proteins [85-
87]. However, CCHFV is able to avoid recognition by RIG-I by processing the 
5’RNA termini of the genome, thereby delaying initial induction of IFNs [88]. 
The new animal models also showed the importance of a functional IFN 
response in controlling CCHFV replication with more severe symptoms and 
higher levels of viral replication in IFN type I knock-out mice compared to wild 
type mice [79, 80].  
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Nitric oxide 
Nitric oxide, NO, is another mediator of the innate response, which can be 
induced either directly by virus or through cytokine dependent activation [89]. 
In vitro experiments have shown that NO can reduce CCHFV replication [90].  
Natural killer cells 
Natural killer (NK) cells play an important role in the early anti-viral defense. 
They have a complex regulation and do not act on pathogen-specific antigens 
but rather on the NK cell activation and inhibitory receptors expressed on cells. 
If activated they can induce apoptosis in the target cell [91]. In CCHF patients, 
one study found greater number of circulating NK cells in fatal cases [92] while 
another found no correlation between mild and severe CCHF [93]. In vivo 
experiments have shown activation of NK cells but an overall loss over time 
[80]. 
 
4.2 MACROPHAGES AND DENDRITIC CELLS 
Antigen-presenting cells (APCs), including macrophages and dendritic cells 
(DCs), are important members of the immune system as they present processed 
antigens on their surface to T cells. They express both class I and class II major 
histocompatibility complex (MHC) molecules.  
For Ebola it has been hypothesized that infection of macrophages and dendritic 
cells is crucial to pathogenesis, as this leads to the release of proinflammatory 
cytokines and other mediators, causing impairment of the vascular and 
coagulation systems that ultimately lead to multiple organ failure and possibly  
death [94].  
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Macrophages 
Macrophages are phagocytosing cells that in addition to their role as APC also 
can employ a battery of innate immune mechanisms for initial anti-viral defense 
[95]. An in vitro study have shown that they produce cytokines upon CCHFV 
infection [96] and a CCHF patient study found a correlation between elevated 
levels of neopterin, a monocyte/macrophage activation marker, and disease 
severity, indicating that macrophages could have a role in CCHF disease 
exacerbation [97]. Recent work using the new animal model found that only one 
macrophage population out of the two studied in the spleen was capable of 
upregulating MHC class II molecules, indicating a possible partial impairment 
of the ability to activate the adaptive immune system [80]. 
Dendritic cells 
Dendritic cells have a crucial role as a bridge between the innate and adaptive 
immune response. They normally reside in peripheral and lymphoid tissues in 
an immature form where they acts as sentinels sensing the antigenic 
microenvironment and capture antigens. When they encounter an antigen they 
undergo maturation, release cytokines as well as migrate to regional lymph 
nodes where they present the antigen to and thereby activate naïve T cells [98]. 
They can also become activated by proinflammatory cytokines such as TNFα 
[99]. 
 In vivo experiments showed no increase of MHC class II molecules in DCs 
during CCHFV infection [80] while in vitro studies of CCHFV-infected 
monocyte-derived DCs (moDCs) have shown that they are activated to the extent 
that they release cytokines (TNFα, IL-6, IL-10 and IL-8) and become partially 
matured [96, 100]. For Ebola and Marburg it has been shown that infected DCs 
aren’t able to initiate an effective adaptive immune response and support T cell 
proliferation [101-103]. But whether something similar is true for CCHFV 
remains to be investigated. An active adaptive immune system is thought to be 
important for survival as fatal cases of CCHF rarely develop an antibody 
response [57, 61].  
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4.3 ADAPTIVE IMMUNE SYSTEM 
The adaptive immune system manifests high specificity for its target antigens. It 
is primarily based on the antigen specific receptors expressed on the surfaces of 
T and B lymphocytes [84]. 
The humoral response is accomplished by B cells. They are APCs that produce 
cytokines and are defined by their production of antibodies that bind and 
potentially neutralize pathogens [84]. In vivo studies have shown activation of B 
cells during infection, followed by decrease in B cell numbers, which is in 
accordance with the lymphocyte depletion observed in patients [80-82].  
The cell mediated response consists of T cells, defined by their cell-surface 
expression of receptors that bind processed antigens displayed by APCs [84]. 
They have several subtypes, including cytotoxic T cells and helper T cells. An 
investigation of lymphocyte levels in CCHF patients found increased levels of 
cytotoxic T cells among fatal compared to nonfatal cases of CCHF but no change 
 in the helper T cells [93].  
 
4.4 CYTOKINES 
Cytokines are cell-signaling proteins that mediate and modulate immunity, such 
as interleukins, IFNs, TNFα, chemokines, migration inhibitory factor, and 
transforming growth factor β [104]. For Ebola, it has been found that 
proinflammatory cytokine release could lead to vascular permeability and 
ultimately hypotension, shock and organ failure [94, 95, 105]. The new CCHF 
animal models have showed increased levels of proinflammatory cytokines, 
TNFα, IL-6, IFN-γ and IL-10 [80, 83]. Several studies of CCHF patients have 
also found elevated levels of proinflammatory cytokines, which was correlated 
to disease severity and death [106-108]. All patient studies found increased 
levels of TNFα, two found higher levels of IL-6 and IL-10 and one found higher 
IFN-γ. Unfortunately, the studies had different sampling times and often only 
one sample could be taken from each patient making comparison difficult. In 
vitro experiments show that moDCs and macrophages release proinflammatory 
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cytokines upon infection [96, 100] and supernatant from infected moDCs could 
activate endothelial cells mainly by released TNFα [109]. 
 
4.5 PROPOSED PATHOGENESIS 
The pathogenesis of CCHFV remains poorly understood. As previously stated 
most of the cases occur in remote regions and the high virulence of the virus 
limits laboratories studies. Most of the knowledge therefore comes from a few 
pathological studies, the relatively new animal models, and similarities to other 
viral hemorrhagic fever viruses and their pathogenesis. 
The primary targets for CCHFV during infection has been suggested to be 
endothelial cells, macrophages, DCs and hepatocytes [81, 83]. As with other 
viral hemorrhagic fevers, the endothelium plays an important role and vascular 
dysfunction would account for the characteristic rash seen in CCHF as well as 
contribute to platelet aggregation and activation of the coagulation cascade [20, 
110]. The effect on the endothelial cells that lead to the vascular permeability 
could either be a direct result of viral infection or an indirect effect of the host’s 
immune response through soluble factors [111].  
Direct effects 
There is evidence of endothelial activation and damage in CCHF patients where 
levels of sICAM-1 and sVCAM-1 were correlated to disease severity [112, 113] 
and in vitro CCHFV infection has been found to activate endothelial cells 
causing cytokine release and leukocyte adhesion [109]. Viral RNA and antigens 
have also been detected in endothelial cells of the liver, spleen, heart and 
intestinal tissues during necropsy and in the new animal models [81, 83]. 
However the presence of virus in the endothelium at time of death does not mean 
that it was the cause of the vascular permeability, as the dysfunction is apparent 
during early part of the disease [6].  
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Enlarged liver has been reported as one of the symptoms of CCHF [1, 54] with 
necrosis of liver found at autopsy [81]. It was suggested to be due to high viral 
replication, which is supported by results found with the new animal model 
where enlarged livers was only found in animals with high viral load in the liver 
[79, 83]. Further support comes from recent in vitro experiments on hepatocytes 
showing that CCHFV infection could induce apoptosis and replicate to high 
titers [114].   
In vitro studies of direct CCHFV infection found no effect on permeability in 
epithelial cells [115, Paper III]. Indicating that other factors most likely cause 
the vascular leakage. This is in line with what has been observed for Ebola virus 
where the vascular leakage is not caused by direct infection but rather due to the 
effects of soluble mediators [104].  
The viral replication does not appear to cause vascular leakage but lead to 
activation, release of cytokines and the recruitment of leukocytes in endothelial 
cells. In contrast, high viral replication in the lymphoid organs could be an 
explanation for the observed lysis and necrosis of the liver and spleen. 
Indirect effects 
Indirect effects of CCHFV infection is not fully understood although the release 
of proinflammatory cytokines have been well documented both in patients, 
animal models and in vitro [6, 83, 96, 100, 108, 109, 114]. Low levels of 
cytokines work locally, while excess amounts can have a systemic effect, a so 
called cytokine storm that subsequently could lead to vascular leakage and 
hemorrhage and ultimately and organ failure. Macrophages and moDCs have 
been shown to be productively infected and release cytokines [96, 100]. 
Cytokines-hyperactivated monocytes and macrophages could be the cause of the 
hemophagocytosis that has been demonstrated in a number of CCHF patients 
[116-118].  
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At present it is not known if the APCs are able to initiate an effective T cell 
response but fatal CCHF patients rarely develop or show a late antibody response 
indicating that the adaptive response is either suppressed or not fully activated. 
The combination of high viral replication, cytokine storm, endothelial activation 
and organ necrosis could be what ultimately leads to the shock and multiple 
organ failure observed in severe CCHF.  
  20 
5 POLARIZED CELLS 
Polarized cells are found throughout the human body and act as a boundary 
between different environments, for example epithelial cells lie between tissues 
and the extracellular environment and endothelial cells line the inner surface of 
blood vessels and acts as a barrier between blood and tissue. They often 
constitute the first line of defense against the environment and regulate the 
passage of substances into and out of organs such as the gut, lung, liver and brain.  
Polarized cells have an asymmetric plasma membrane with an apical and a 
basolateral side [119]. They are organized as selectively permeable continuous 
sheets that separate the two different sides, where the apical side face the lumen 
i.e. the outside for the epithelial cells and the blood for the endothelial cells while 
the basolateral side face the tissues and is in contact with the neighboring cells 
and the underlying extracellular matrix. The two domains also have distinct lipid 
and protein compositions which is generated and maintained by a specific sorting 
machinery [119, 120].  
The space between the neighboring cells is sealed by junctions which restrict the 
paracellular transit of ions and macromolecules and separate the two sides of the 
cells [121]. There are different junctions between the cells, the tight junctions 
are the most apical of them, located at the boundary between the apical and the 
basolateral domain of the cells [121]. They tightly seal the space between 
neighboring cells, preventing the passage of fluids, electrolytes and 
macromolecules between the cells [121]. Adherens junctions are located on the 
basolateral side of the cells. They mediate cellular polarization and 
organogenesis. There are also gap junctions that form channels between the 
neighboring cells, allowing intercellular dissemination of small molecules [121].  
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Transepithelial resistance (TER) 
To study polarized cells in vitro, the cells can be grown on permeable support, 
where the cells have free access to medium from both sides and samples can be 
taken from both sides. Since electrical conductivity is almost limited to the 
paracellular ion flux, the transepithelial resistance (TER) across the monolayer 
is a good marker of the development of tight junctions and can therefore be used 
to describe cell monolayer integrity [122]. The “chopstick system”, consisting 
of 2 electrodes stuck together, one for each side, is easy to use for routine 
determination of TER in filter-grown monolayers. 
 
5.1 POLARIZED CELLS AND VIRUS INFECTION 
As cellular proteins and receptors could be differently distributed on the different 
sides of a polarized cells [120], it could be a limitation for viral entry and release. 
While some viruses are restricted to entry from a specific side, others viruses 
like influenza and poliovirus, have little or no preference [119]. Many virus 
receptors are not located on the apical side, but at the basolateral side, rendering 
intact cells layers resistant against many viral infections, such as HSV-1, 
poliovirus, reovirus and human adenovirus [123].  
Viruses have therefore been forced to come up with ways to overcome this. 
Some viruses use more than one receptor, this appear to be the case for herpes 
simplex virus [124]. While others, like rotavirus, disrupts the tight junctions 
between the cells to get access to the basolateral side [125]. It has also be shown 
that the same virus using the same receptors can enter from different sides in 
different epithelial cells demonstrating cell type specificity [126]. The junctions 
may also be remodeled by cytokines to allow the passage of activated infected 
immune cells across the epithelial border [123]. Recently another way was 
shown, where adenovirus infected macrophages enabled the translocation of the 
viral receptor from the basolateral to the apical side, thereby enabling entry of a 
virus that normally requires basolateral access [127].  
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CCHFV has been found to primarily enter from the basolateral side [115, Paper 
III] although the addition of infected moDCs lead to more virus entry from the 
apical side, the reason for this is at present not known [Paper III].  
Viral release can occur from both sides but can have an effect on whether the 
infection becomes localized (apical release) or systemic (basolateral release) 
[119]. CCHFV has been found to be released from the basolateral side further 
aiding systemic spread [115].  
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6 ENDOCYTOSIS 
Viruses are obligate intracellular organisms and as such they must enter target 
cells in order for successful replication to occur. Different viruses have therefore 
developed different ways of entering and the route of entry can also vary 
depending on cell type. Most viruses do however exploit the cell’s preexisting 
endocytic routes in order to gain entry into their target cells.  
Virus endocytosis begins with the virus attaching to cell attachment factors 
and/or virus receptors that in turn induces a conformational change of the virus 
and/or signal cascade within the cell which promotes the internalization of the 
virus. Most endocytosis routes transports the encapsulated virion to the early 
endosome, through the multivesicular body to the late endosome and further on 
to the lysosome. In order for the virus to escape degradation in the lysosome it 
therefore has to penetrate the endosomal membrane at some point and deliver its 
genome to the appropriate replication site. Enveloped viruses fuse the viral and 
cellular membranes to release their genome into the cytosol while non-enveloped 
viruses use membrane-lysis or pore-formation [128]. The catalytic event that 
determines when release occurs is usually pH, where the acidic environment 
inside the endosome or lysosome induces conformational changes in the virion 
structure that enables fusion [128].  
The most common viral entry route is clathrin mediated endocytosis (CME), 
followed by caveolae and a number of clathrin and caveolae independent routes. 
The virus could also be engulfed and enter through macropinocytosis or 
phagocytosis. A few enveloped viruses have also been shown to enter by fusion 
with the plasma membrane for example herpes simplex-1 and HIV [128]. But as 
the same viruses are also endocytosed at the same time it is difficult to determine 
if plasma membrane fusion lead to productive infection. Using the cells own 
machinery when entering can have many advantages for the virus, it not only 
offers a protected environment for the virus to pass through the actin cortex and 
the dense cytoplasm while transporting it to necessary sites and organelles where 
virus penetration can occur but it also helps the virus to escape recognition by 
the immune system as no virus specific parts are left at the plasma membrane.  
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Figure 5: Schematic depiction of different endocytosis routes used by viruses. a) 
Clathrin mediated endocytosis, b) Caveolae, c) Lipid raft, d) Clathrin- and 
Caveolae-independent endocytosis and e) Macropinocytosis 
 
6.1 CLATHRIN MEDIATED ENDOCYTOSIS  
CME is a constitutive event that is found in all eukaryotic cells and normally 
used to take up cargo and nutrients, control many plasma membrane activities 
and is fundamental in neurotransmission. Clathrin is a self-polymerizing protein 
that is composed of three heavy and three light chains that together form a 
triskelion shape consisting of three bent limbs radiating from a centre [129]. It 
can polymerize into either flat lattices or cages and is not only involved in 
endocytosis from the plasma membrane but is also involved in the endosomal 
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sorting complex required for transport (ESCRT)- dependent cargo sorting at the 
endosomes, protein secretion from the trans-Golgi network and mitosis [129]. 
Clathrin can be found in stable islands in the plasma membrane or become 
recruited through receptor mediated signaling. Some viruses like Reovirus, 
Influenza A and Vesicular stomatitis virus (VSV) have for example been shown 
to induce de novo formation at the site of binding [130]. The clathrin triskelions 
form a lattice-like coat on the cytoplasmic surface of the plasma membrane. 
Binding of clathrin to the membrane is mediated by adaptor protein 2 (AP2) that 
links the membrane cargo to clathrin and accessory proteins like epsin and 
AP180 [129]. AP2 is considered to be an absolute requirement for CME [129], 
some are however controversially suggesting that for example VSV can enter by 
CME without AP2 [130]. Yet this is still very controversial and needs to be 
further analyzed. 
The process of clathrin coated invagination continues, leading to the formation 
of deeply invaginated pits and the formation of a vesicle neck. Clathrin 
polymerization helps in the formation and constriction of the vesicle neck, 
helping to bring the membranes surrounding the neck into close apposition 
[131]. The fission of the vesicle is then made by the membrane scission protein 
dynamin, a large GTPase that form a helical polymer around the vesicle neck 
[130]. After internalization the clathrin coat is removed by uncoating proteins, 
Hsc70 and auxilin to form a naked vesicle [132]. The vesicle and its cargo is 
then transported to Rab5 positive early endosomes while the clathrin triskelia 
and accessory proteins are recycled to perform more CME. Some virus like VSV 
exit in the early endosome while others like Influenza A continues through the 
multivesicular body to fuse with the late endosome [130]. It is thought that the 
later stages of endocytosis (formation of curved coats and vesicle budding) can 
occur independently of what cargo is present in the coated pit. Thus, cargo 
recruitment to the clathrin-containing lattice structure is the key sorting step 
defining the specificity of the internalization process [132]. 
 
  26 
The first virus that was shown to enter by CME was Semliki Forest virus (SFV) 
[133] but today CME is well established as the main entry route for viruses [130]. 
Yet in some cases like for Influenza A and lymphocytic choriomeningitis virus, 
CME is only one of several entry pathways that the virus can use [130].  
 
6.2 CAVEOLAE AND LIPID RAFT ENTRY 
Caveolae and lipid rafts are found in cholesterol rich domains of the plasma 
membrane and are involved in cellular endocytic processes and signaling. Lipid 
rafts is a specialized cholesterol- and sphingolipid-enriched membrane 
microdomain that can influence membrane fluidity, receptor clustering and 
assembly of signaling molecules [130]. Caveolae are seen in electron microscope 
as small regular shaped membrane invaginations [134] and can exist either as 
single caveolae or clusters of multiple caveolae [135]. They are important in the 
regulation of various signaling processes, such as nitric oxide activity, and in 
cholesterol uptake and trafficking [134]. The major structural protein, caveolin-
1 forms a coat-like surface around the vesicle and is necessary for the formation 
of invaginated caveolae [135]. Caveolin is present in the plasma membrane as 
well as on intracellular structures [135]. It is found in nonmuscle cells with the 
exception of neurons and leukocytes [131]. Expression of caveolin-1 alone is 
sufficient to cause the formation of caveolae [135]. Under normal conditions 
caveolae do not appear to be involved in endocytosis and are kept at the plasma 
membrane by actin filaments [134]. They do however perform short range “kiss 
and run” movements, but whether this is in fact is endocytosis is not yet clear 
[134]. Although caveolae are not ordinarily internalized they can be if stimulated 
by for example Simian virus 40 (SV40) that initiate a signal cascade that leads 
to the depolymerization of the actin cytoskeleton [135]. The fission protein is as 
for CME, dynamin [135].  
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Caveolae has mainly been suggested to be involved in viral endocytosis for 
members of the polynoma family i.e. SV40, BK and JC virus [130]. Where the 
endocytosed polynoma viruses pass through the early and late endosome and are 
released in the ER. The role of caveolar as a primary route of viral entry has 
however come in question in recent years and it has now been suggested that 
only a fraction of SV40 and probably other polynomaviruses enter via caveolae 
and that the fraction may vary with cell type and virus [130]. The rest use a 
related caveolin-1 independent mechanism. Both routes appear to be sensitive to 
cholesterol depletion, and require Arf1 and dynamic actin [130]. Internalization 
through caveolae also appears to be slower, dynamin-2 dependent and more 
dependent on actin dynamics than the noncaveolar pathway [130]. 
 
6.3 CLATHRIN AND CAVEOLAE INDEPENDENT ENDOCYTOSIS 
As already stated, some viruses have been shown to become endocytosed in a 
clathrin and caveolae/caveolin-1 independent way. The number of viruses that 
can use these routes are expanding but at the moment very little specific 
information exists regarding these routes. For Influenza A it has been shown that 
1/3 of the virus particles are endocytosed in a clathrin and caveolin-1 
independent way and that this infection is just as effective and that trafficking 
through early to late endosomes appear to similar to CME [136]. An IL-2 
tentative route of entry has been suggested for Rhesus rota virus and possibly 
also for SARS virus [130]. In both cases it was shown to be clathrin and caveolin-
1 independent and cholesterol and dynamin dependent. Adeno-associated virus 
2 was recently suggested to enter through the GEEC/CLIC pathway [137], which 
is another clathrin and cavoelin-1 independent route. Not much is known 
regarding this route and so far this is only virus that has been proposed to use 
this route. 
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6.4 MACROPINOCYTOSIS AND PHAGOCYTOSIS 
Macropinocytosis is a cargo triggered endocytosis route which normally is 
activated by growth factor. This triggers the activation of a complex signal 
cascade that induces changes in the actin filaments dynamics and triggers plasma 
membrane ruffling [138]. These ruffles will eventually collapse back towards 
the plasma membrane creating an uncoated irregularly shaped vacuole. It is 
mostly a transient process responsible for the internalization of fluid, solutes and 
sometimes particles into large vacuoles [139]. It is strictly dependent on cortical 
actin but independent of dynamin and does not require binding to a specific 
receptor [140]. The vacuole can become acidified and intersect with endocytic 
vesicles, making it a possible entry pathway [128]. Macropinocytosis is the main 
route of entry for Ebola virus, although a fraction of the virus also uses CME 
[141]. Human adenovirus, Influenza A and Vaccinia virus has also been 
suggested to use this route for part or all of their entry [138]. 
Unlike the other entry routes, phagocytosis is only found in specialized cells 
such as macrophages and amoeba, where it is used for uptake of large particles 
[130]. Mimivirus has been suggested to use phagocytosis [142] while herpes 
simplex virus 1 has been suggested to use phagocytosis-like uptake [143]. 
 
6.5 BUNYAVIRIDAE ENTRY AND RECEPTORS 
Bunyaviridae entry has been shown to be pH dependent with some virus, like 
CCHFV, Hantavirus and Oropouche virus, entering by CME [24, 144, 145, 
Paper I]. While others, like Uukuniemi virus (Phlebovirus) has been shown to 
enter cells mainly through clathrin-independent endocytosis [146] while Rift 
valley fever virus (Orthobunyavirus) was shown to be using caveolae [147].  
Viruses express glycoproteins on their surface, by which they can attach to 
cellular receptors or attachment factors. Although not all viruses require specific 
receptors for attachment and internalization most virus attach to some cellular 
receptor or attachment factor. There are numerous viral receptor expressed on 
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cell surfaces and not all receptors are expressed on all cells. Some viruses have 
therefore evolved to use different receptors depending on the cell their infecting 
[124]. The availability and position of a specific receptor can determine whether 
a virus is able to infect that particular cell [123]. For Bunyaviridae viruses, DC-
SIGN and β3 integrin have been demonstrated as receptors [148, 149]. A recent 
report suggested nucleolin to be essential for CCHFV entry [23], but whether it 
acts as a receptor or an attachment factor aiding in the entry of the virus remains 
to be investigated.   
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7 IN SITU DETECTION OF NUCLEIC ACID  
In situ detection has the advantage of giving the precise and spatial localization 
of specific nucleic acid sequences in their natural setting. This gives the 
possibility to correlate the single cell results to that of the surrounding cells or 
tissue. There are a number of ways to detect nucleic acids in situ. 
 
7.1 ISH AND FISH 
In situ hybridization (ISH) is a technique where labelled DNA probes are 
hybridized to specific target sequence in fixed samples giving a localized 
detection of nucleic acids. It was first performed using radio-labelled probes 
[150] but had limitations in resolution and probe instability, therefore the 
technique was further developed. With the addition of fluorescence (FISH, 
fluorescent in situ hybridization), the method became more applicable and more 
than one target could be detected simultaneously since different fluorophores 
could be used for different targets [151, 152]. The detection can be done either 
directly, so that the fluorescence could be analyzed immediately after 
hybridization, or indirectly, where probes are labeled, for example with hapten, 
and then detected with fluorescent-labeled antibodies against hapten. The 
technique has primarily been used for detection of chromosome abnormalities. 
During the last few years several modifications of FISH have been presented. 
Among them adding locked nucleic acids (LNAs) to improve resolution and 
sensitivity [153, 154]. LNAs are a class of RNA analogs with exceptionally high 
affinity towards complementary DNA and RNA [153].  
Both ISH and FISH have been used for the detection of mRNA in situ, both 
individually and as multiplexed analysis [150, 155-157]. Hybridization-based 
methods are however usually semiquantitative and do not allow precise digital 
quantification of the signals. They can also not discriminate between highly 
similar sequences, making them unsuitable for studying cell-specific allelic 
expression or expression of splice variants [158].  
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7.2 PADLOCK PROBES 
In oligonucleotide ligation assay (OLA), two oligonucleotides bind next to each 
other and are ligated by a DNA ligase if they form a perfect match [159]. This 
allows for the distinction of single nucleotide variants at the ligation junction. 
Padlock probe is a further development of OLA. Instead of having two different 
oligonucleotides, a padlock probe is one long linear oligonucleotide where the 
3’- and 5’ ends bind juxaposed to each other on the target sequence. The ends of 
the padlock probe are joined together by a target-non-complementary DNA 
backbone that is later used as detection site. If the two ends are correctly 
hybridized to the target sequence a nick is formed between them. The nick can 
then be closed by a DNA ligase, creating a closed “locked” circular DNA 
molecule [160]. A locked probe remains attached to its target sequence and can 
withstand highly stringent wash conditions, further reducing the amount of non-
specific signals [160]. The ligated probe can then be detected by labeled 
oligonucleotides towards the target-non-complementary DNA backbone of the 
padlock probe. 
Padlock probe detection is highly specific as two target complementary 
sequences at the correct position are required for ligation and the DNA ligase 
has a strong preference for a perfect match, particular at the 3’-end [161]. 
Mismatched padlock probes will therefore not be circularized. Accordingly, 
padlock probes can therefore be used for detection of single nucleotide 
differences [162, 163] and can easily be utilized against multiple targets with 
limited cross-reactivity between probes [163]. However, to effectively detect the 
padlock probes signal in situ, amplification is needed.  
 
7.2.1 Rolling circle amplification 
Rolling circle amplification (RCA), creates a linear single stranded DNA 
molecule (RCP, rolling circle product) consisting of tandem repeats of the 
complementary sequence of a single stranded circle [164]. If correctly ligated, 
padlock probes can be used as templates for RCA, thereby increasing detection 
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sensitivity. In order for the RCA to proceed more than 1 turn around the 
template, a polymerase with strand displacement activity is needed, Phi29 
polymerase has this. It also has two other important activities for RCA, 3’-5’ 
exonuclease activity on single stranded DNA as well as polymerase activity 
[165, 166]. This means that it can remove the non-base-paired nucleotides 
downstream of the padlock probe and when reaching the probe bound to the 
target, it can perform polymerization using the target strand as a primer. RCA of 
a ligated padlock probe can also be initiated by an external primer. Alternatively, 
the DNA can be cut site-specifically before amplification by introducing an G:A 
mismatch, where the padlock probe contains a G which is mismatched with an 
A in the target molecule [167]. The padlock probe should then be designed so 
that the mismatch is located at the end of the padlock probe binding site on the 
target sequence. MutY enzyme will then remove the mismatched A in target 
molecule, leaving an abasic site in the target molecule. This site is then 
recognized and cleaved by Endo IV, enabling free access for the Phi29 
polymerase to start the RCA [167]. 
RCA is a very specific way to detect padlock probes since only ligated probes 
can serve as templates and the produced RCPs will still remain attached to the 
target sequence [168]. The long RCP spontaneously collapses into a micron-
sized object that can be visualized by hybridization with fluorescence-labelled 
oligonucleotides [169] , which have the same sequence as the backbone of the 
padlock probe. As the RCP consists of repeated sequences, this will create a local 
enrichments of fluorophores over background, visual as a single dot in the 
microscope [169, 170]. The fluorescent dots can then be quantitatively counted 
[171]. Due to the specificity of the padlock probe, RCA can be performed against 
multiple nucleic acid targets. Padlock probes and RCA was first used to detect 
mitochondrial DNA in situ, where the DNA first was made single stranded to 
enable hybridization and ligation of the padlock probe [172].  
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Figure 6: Schematic representation of RNA detection using LNA-primer, 
padlock probe and target-primed RCA. 
 
7.2.2 RNA detection in situ using padlock probes and RCA 
RNA can serve as template for the ligation of padlock probes but it has less 
sensitivity and specificity compared to DNA template ligation [165, 173]. A way 
to overcome the problems with low sensitivity and specificity of RNA template 
ligation in situ, is to first perform a reverse transcription step where a primer 
containing LNA modified bases is used to first convert the RNA into 
complementary (c) DNA. The LNA primer then ensures that the cDNA remains 
attached to the target RNA even after RNaseH digestion as the LNA primer 
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protects bound RNA from being degraded [174]. The cDNA can then be detected 
by padlock probes and RCA. This method has been used to distinguish single 
nucleotide differences of actin in cultured cells and tissue, and had a detection 
efficiency of approximately 30% of available transcripts as determined by qPCR 
[174]. With the addition of RCA and LNA primers, RNA viruses could 
effectively be detected with padlock probes both in solution [175] and in situ 
[Paper II]. 
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8 PRELIMININARY RESULTS  
CCHFV entry is independent of human αV, α5, β3 or β5 integrins. 
We have previously shown that CCHFV enters by clathrin-mediated endocytosis 
[Paper I], but there is, however, no clear data on which receptor CCHFV use. A 
number of viruses have been shown to use integrins as cellular receptors including 
another Bunyaviridae member, Hantavirus, that was shown to use β3 integrin 
during entry [148]. Although not the only receptor for Hantavirus, it has been 
suggested that the binding of hantavirus to β3 integrins could have an effect on 
cellular integrity by relocation of VE-cadherin and thereby be a cause for the 
vascular permeability observed in patients [176, 177]. Integrins are 
transmembrane glycoproteins that consist of an α and β subunit and mediate cell-
matrix and cell-cell adhesions [178]. The number of varieties of α and β subunits 
produce ligand selectivity to extracellular matrix. Integrins transmit signals, 
outside-in and inside-out and regulate cell survival and migration [123]. 
To investigate if CCHFV could be using human αV, α5, β3 or β5 integrins during 
their entry, we used cells that were manipulated to express human integrins to see 
if this increases internalization as compared to the control cell line. We used 
Chinese Hamster ovary (CHO-B2) cells, transfected with cDNA to continuously 
express either human αV integrin (CHO-B2-αV) or α5 integrin (CHO-B2-α5) as 
well as Chinese hamster melanoma (CS1) cells that had been transfected with 
cDNA encoding either human β3 (CS1-β3) or β5 (CS1-β5) integrin protein. The 
CHO-B2 cells were grown in Dulbecco’s modified Eagle´s minimal essential 
medium (DMEM) with 10% FBS, 2mM L-glutamine, 1% NEAA, 100units/ml 
penicillin, 100ug/ml streptomycin, and 10mM hepes with addition of 700µg/ml of 
geneticin (all from Gibco, Life technologies) for the CHO-B2-αV and CHO-B2-
α5 cells. The CS1 cells were grown in RPMI medium with 10% FBS, 2mM L-
glutamine, 100units/ml penicillin, 100ug/ml streptomycin, and 10mM hepes and 
with the addition of 500µg/ml of geneticin (all from Gibco, Life technologies) for 
the CS1-β3 and CS1-β5 cells. Cells were seeded on 24 well plates and grown to 
80% confluence. The same number of cells was always used for all compared cell 
lines, as CS1 cells grow as suspension cells due to the lack of anchoring integrins. 
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Cells were infected with CCHFV Ibar 10200 (moi 1, as determined by Vero 
titration) for 1h at 37°C in a 5% CO2 humidified atmosphere. The adherent cells 
were rinsed twice in PBS and the nonadherent cells were centrifuged and rinsed 
twice with PBS before replenished  in fresh medium, added to the original well 
and incubated for 24h at 37°C in a 5% CO2 humidified atmosphere. At which point 
the nonadherent cells were centrifuged and cell pellet added TRIzol, the lysed cells 
were then combined with lysed attached cells in the original well. All handling of 
the virus was carried out at the BSL-4 facility at the Public Health Agency of 
Sweden, Solna, Sweden. Total RNA extraction, cDNA synthesis and quantitative 
real-time PCR was performed as previously described [25]. Amplifications was 
always performed in triplicates and relative amount of CCHFV S segment 
transcripts were calculated with the 2-(∆∆Ct) method in relation to GAPDH (and 
with the reference Ct set to 1). All assays included noninfected cells and were 
always negative for CCHFV RNA. 
Surprisingly, we found that cells not expressing human αV, α5, β3 or β5 integrins 
had the highest level of infection. These data suggest that these integrins are not 
essential for CCHFV entry. In paper III in this thesis, we hypothesize that the shift 
towards apical entry that occur when infected dendritic cells or their supernatant 
is added could be explained by a translocation of an viral receptor from the 
basolateral side to the apical side. This has previously been shown for adenovirus 
infected macrophages that release soluble factors, including IL-8, causing a 
translocation of the viral receptor αvβ3 from the basolateral to the apical side 
[127]. We can here show that CCHFV infection is not dependent on either human 
αV, α5, β3 or β5 integrin. The reason for the change in entry side in polarized cell 
is therefore not due to translocation of these integrins and therefore remains to be 
further investigated.  
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Figure: Cells expressing or lacking human integrins were infected with CCHFV 
for 24h and then analyzed by RT-PCR for CCHFV RNA levels. Results are 
shown as fold change to noninfected cells. A) CS1 cells lacking or expressing 
human integrins β3 or β5. CHO cells expressing or lacking (B) human integrin 
αV or (C) human integrin α5.  
   
A 
B 
C 
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9 RESULTS AND DISCUSSION  
9.1 CCHFV ENTRY (PAPER I) 
In order for virus to replicate, they have to enter a target cell. Viruses have 
therefore evolved a of numbers ways to do this. Hantavirus, another 
Bunyaviridae member, was known to enter cells though clathrin-mediated 
endocytosis in a pH-dependent manner [144] but nothing was known regarding 
CCHFV’s entry. 
We therefore sought to investigate two common viral entry routes; the clathrin-
mediated and caveolae endocytosis by reducing the expression of the main 
proteins of each pathway, clathrin and caveolin-1 respectivly. The siRNA 
knockdown of caveolin-1, as confirmed by qPCR and western blot, had no effect 
on the level of CCHFV infection, suggesting that caveolae is not necessary for 
CCHFV infection. This was further confirmed by the fact that Vero E6 cells, one 
of the most commonly used laboratory cell line for CCHFV infection was 
discovered to have no or very low levels of caveolin-1, yet it had the highest 
level of CCHFV infection of the investigated cell lines in this study.  
 
On the contrary, by treating cells with sucrose or CPZ, we found an indication 
that CCHFV could use clathrin-mediated endocytosis. This was confirmed by a 
drastic reduction of infection when clathrin protein and mRNA levels were 
reduced. We therefore concluded that CCHFV most likely enters through 
clathrin-mediated endocytosis. However, we could not completely knock-down 
clathrin, and in accordance with this, some CCHFV infection could still be 
detected in the clathrin knock-down treated cells. Thus, we could not exclude 
that CCHFV could also use a different clathrin-independent route for entry. 
As clathrin-mediated endocytosis transports virus to the early endosomes and 
many viruses require a drop in pH to induce a conformational change in their 
glycoproteins and thereby escape from the endosome, we also wanted to 
investigate pH-dependency. By treating cells with chemicals known to disrupt 
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the acidification of the endosome, we could determine that CCHFV entry is pH-
dependent.  
Furthermore, in this paper we also investigated whether membrane-bound 
cholesterol was needed for CCHFV entry by treating the cells with a cholesterol-
depletion drug. Caveolae and lipid raft endocytosis are located      in cholesterol-
rich parts of the membrane and are therefore highly dependent on cholesterol but 
CME also requires cholesterol. By treating the cells at various time-points 
before, during or after infection we concluded that CCHFV binding was 
unaffected by cholesterol depletion but that cholesterol was needed during or 
soon after entry and possibly also during later event, such as transcription or 
replication.  
Since this paper was published another study has confirmed our results showing 
that CCHFV enters by clathrin-mediated endocytosis and that CCHFV escapes  
from the early and not the late endosome [24]. 
 
9.2 IN SITU DETECTION OF CCHFV RNA (PAPER II) 
Single cell detection of RNA has several advantages compared to other 
molecular methods as it will give the expression level for each cell, which can 
vary significantly from the mean expression detected in a cell population [179, 
180]. Visualization of single RNA molecules in situ will give the spatial location 
as well as reveal potential interactions within the cell, differences that would not 
be detected by for example PCR. We therefore wanted to develop an in situ based 
method where we could detect individual CCHFV RNA transcripts using a 
fluorescent microscope.  
CCHFV is a negative single stranded virus, meaning that during its replication 
it must produce a positive RNA strand for transcription and replication. We 
therefore wanted to target the different strands and be able to differentially detect 
them to investigate their cellular location during infection. Reverse transcription 
together with specific detection by padlock probes and target-primed RCA had 
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previously been used to detect individual RNA molecules in situ [174]. Yet it 
had never been done on negative stranded RNA viruses.  
Therefore, we investigated if this technique could be used to detect and 
differentiate between CCHFV vRNA and cRNA in fixed cells as well as 
combining this with detection of CCHFV proteins. Cell were infected for various 
times and fixed. vRNA or cRNA was then reverse-transcribed into cDNA by 
using individual LNA-containing primers. The LNA primer protects the target 
from being degraded during RNaseH treatment, leaving the cDNA still attached 
to the target. Each cDNA is then detected by a padlock probe which if correctly 
ligated becomes circularized. The target is then site specifically cleaved to 
produce a starting point for the RCA. The resulting RCP is detected by 
hybridization of fluorescently labelled oligonucleotides, making them visual as 
single dots that then can be digitally counted. 
The method worked well, however some false-positive signals could still be 
detected in the technical controls, but they were always significantly lower than 
signals observed in infected cells. Both vRNA and cRNA could be detected 
individually and together. vRNA was found located throughout the cytoplasm 
while cRNA was more concentrated to specific parts of the cell. The assay could 
also be used to investigate co-localization between viral RNA and viral proteins. 
cRNA was found to co-localize with CCHFV NP within the same cellular 
structures while vRNA showed no intra-cellular co-localization with CCHFV 
NP.  
By combining in situ reverse transcriptase by LNA-primer with detection using 
padlock probes and RCA, we were able to detect the different strands as 
individual dots when looking in a fluorescence microscope. Unfortunately due 
the positioning of the primer and probe, we could not discriminate between 
cRNA and mRNA. While these techniques has previously been used for the 
detection of positive stranded RNA viruses [181], this was the first time it was 
used to detect a negative stranded RNA virus in situ and distinguish between  
different RNA strands. 
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9.3 IN VITRO PATHOGENESIS MODEL (PAPER III) 
To understand the molecular mechanism behind CCHFV’s pathogenesis, there 
is a need to investigate virus-host interaction. To date, there are no good in vivo 
or in vitro models available for this. A transwell assay has previously been 
developed and used to study the direct effect of CCHFV infection on cell 
integrity. It was then found that infection was not sufficient to cause increased 
permeability and it was suggested that other factors therefore most likely were 
involved. However this assay was based on canine cells. Therefore in order to 
confirm these data, we have here established an in vitro assay based on human 
epithelial cells. Moreover, this assay was used to study cell-cell interaction, to 
further assess other reasons behind the increased vascular permeability observed 
in CCHFV. 
We infected the human polarized cells and could confirm that direct infection 
and replication is not sufficient to cause disruption in cellular integrity. Further 
indicating that other elements most likely are important in the development of 
the vascular leakage observed during CCHF. Elevated levels of cytokines has 
been detected in CCHF patients and in the new animal models [80, 83, 107, 108]. 
In addition, in vitro experiments have shown that infected moDCs release the 
same cytokines that has been found in clinical and in vivo studies [96, 100]. DC 
has also been suggested to be one of the primary target cells for CCHFV 
infection [81, 83] and to play a role in spreading the virus.  
Infected moDCs was therefore added to our polarized human epithelial cells to 
study if they affected the permeability of these cells. No change in permeability 
could be detected regardless of the side the infected moDCs were added to. 
Though we could detect CCHFV RNA in the epithelial cells confirming that DCs 
could have a role in the systemic spread of the virus. However, quite surprisingly 
we could detect a higher level of infection in the epithelial cells when the infected 
moDCs were added on the apical side of the epithelial cells. This is in contrast 
to the primarily basolateral viral entry observed when only virus was added. To 
determine if the moDCs had an active role in the apical entry we added 
supernatant from infected moDCs to either side of the polarized epithelial cells. 
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Again, a primarily apical entry for CCHFV was observed, suggesting that 
released soluble factors from infected moDCs might affect CCHFV entry. 
A recent report on adenovirus, which exclusively enters from the basolateral 
side, found entry to occur from the apical side if infected macrophages were 
added on that side. This was mainly due to released IL-8 causing a translocation 
of the adenovirus receptor human integrin αvβ3 from the basolateral side to the 
apical side [127]. Elevated levels of IL-8 has been shown for CCHFV both in 
patients and in vitro [96, 109, 114, 182]. It is currently not clear what receptor 
CCHFV is using and in the preliminary results section of this thesis we show 
that CCHFV entry is independent of human αv or β3 integrin. The observed shift 
towards apical entry must therefore be due to something else. It can however not 
be ruled out that CCHFV-infected moDCs can cause translocation of another yet 
unknown receptor from the basolateral side to the apical, thereby assisting viral 
entry from the apical side.  
More experiments are however needed in order to determine the reason for the 
change towards apical entry for CCHFV. As well as more research on possible 
CCHFV receptors and the role of macrophages and dendritic cells in 
disseminating and aiding CCHFV entry. Knowledge regarding the exact 
mechanism behind CCHFV’s pathogenesis would greatly improve research on 
 specific treatments. 
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10 CONCLUDING REMARKS  
Crimean-Congo hemorrhagic fever virus can cause severe human disease and 
unfortunately not much is known about this virus. Work in this thesis has 
contributed to new knowledge regarding the entry route into cells and established 
a new technique to visualization and discriminate between vRNA and cRNA in 
a single cell. Within this thesis I also established an in vitro model to study cell-
cell interactions that be used to study molecular mechanisms behind CCHFV’s 
pathogenesis. 
Viruses have to enter a host cell in order to replicate its genome, in paper I, we 
found a strong dependency for clathrin protein for CCHFV’s entry. We could 
also demonstrate a dependence for a lower pH during CCHFV entry. We 
therefore concluded, and this has since been confirmed by another group, that 
CCHFV enters through clathrin-mediated endocytosis in a pH-dependent 
manner. However, more research is needed to characterize more specific details 
regarding CCHFV’s entry and uncoating process, work that potentially could 
contribute to the development of new antivirals. 
 In paper II, a new technique for the visualization of individual RNA molecules 
for CCHFV was established. We used this technique to detect the different 
strands of RNA that is produced during CCHFV’s replication as well as to 
investigate their potential co-localization with the viral nucleocapsid protein. 
vRNA was detected throughout the cytoplasm and did not co-localize with 
CCHFV NP while cRNA was found to be more concentrated to particular 
regions within the cell. cRNA was also found to co-localize with the viral 
nucleocapsid protein within these regions. This new technique enables 
visualization of vRNA and cRNA transcripts and their interaction with viral 
protein, which could be used to characterize different steps of the viral 
replication cycle.  
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In paper III, a new in vitro model system is presented where moDCs were added 
to polarized human epithelial cells to study the effect on the epithelial cell 
integrity. This was done as a model system of the vascular permeability that is 
observed in CCHF patients. While neither direct infection with virus nor the 
addition of moDCs had an effect on the integrity of the epithelial cell layer in our 
model. Surprisingly, we observed an entry shift from a primarily basolateral entry 
when only virus was added, to a primarily apical entry when CCHFV-infected 
moDCs were added. The shift in entry for CCHFV was also observed when 
supernatant from infected moDCs were added apically. The reason for this 
remains unclear but we speculate that it could be due to released soluble factors 
from the dendritic cells that possibly could cause a translocation of a yet unknown 
viral receptor from the basolateral to the apical side. However this needs to be 
further investigated. 
Taken together, we established several new in vitro model systems to study 
CCHFV’s interaction with host cells. We also show data demonstrating the entry 
pathway for CCHFV into mammalian cells. These data and tools will hopefully 
facilitate and promote research on virus-host interactions which in turn may result 
in the development of new anti-virals. 
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11 POPULÄRVETENSKAPLIG SAMMANFATTNING 
Krim-Kongo blödarfeber (CCHF) är en allvarlig sjukdom som drabbar människor. 
Den kan i allvarligast fall ge mycket svåra symtom med blödningar och organ 
kollaps. Sjukdomen orsakas av viruset Krim-Kongo blödarfebervirus (CCHFV), 
som i naturen sprids av fästingar. Människor smittas genom fästingbett, hantering 
av smittade eller fästingbärande djur eller vård av andra CCHF sjuka människor. 
Det finns idag ingen specifik behandling eller vaccin utan man kan bara behandla 
symtomen. Viruset finns idag i delar av Afrika, sydöstra Europa och sydvästra 
Asien. Flest fall förekommer för tillfället i Turkiet som sedan 2002 har haft över 
6000 fall. CCHFV är ett negativt enkelsträngat RNA virus, där RNA:t eller 
arvsmassan som det också kallas är uppdelat på tre olika segment som tillsammans 
kodar för virusets 4 strukturella proteiner. Att arvsmassan är av negativ polaritet 
gör att viruset först måste tillverka en likadan positiv mall innan det kan utnyttja 
cellens maskineri för att tillverka sina egna proteiner och nytt virus RNA. Arbetet 
i den här avhandlingen har gjorts för att öka kunskapen om hur CCHFV tar sig in 
i celler, dess replikation och hur det eventuellt kan orsaka sjukdom. Kunskap som 
förhoppningsvis kan leda till bättre behandlingsmetoder. 
Virus kan inte replikera sin arvsmassa själv, utan är beroende av värdceller för att 
kunna föröka sig. För att kunna göra det måste viruset ta sig in i cellen. Det kan 
virus göra på många olika sätt och i denna avhandling undersöker vi två av de 
vanligaste sätten för virus att ta sig in i celler för att se om CCHFV använder dessa. 
Det gjorde vi bland annat genom att nedreglera två cellproteiner som är 
nödvändiga för de olika vägarna. På så vis kunde vi komma fram till att CCHFV 
behöver cellproteinet clatrin, för att kunna ta sig in i cellen. Vi kom också fram till 
att viruset behöver en pH-sänkning för att kunna ta sig in i cellen. I andra virus 
brukar en pH-sänkning medföra en förändring i ytproteinerna hos viruset, så att 
det kan ta sig ur den vesikel som det transporterats in i och börja replikera sin 
arvsmassa. Exakt hur pH värdet påverkar CCHFVs ytprotein är dock än så länge 
oklart. 
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Vi har också använt en ny teknik för att kunna studera CCHFVs replikation, där 
vi visualiserar och kan skilja positivt och negativt strängat virus RNA åt, inne i 
fixerade celler. Teknik som denna är viktiga verktyg för att lära oss mer om hur 
viruset replikerar i cellen. Med denna metod kan man se varje enskilt RNA som 
en lysande punkt inne i cellen när man studerar dem i fluorescence mikroskop. Vi 
kunde även färga för virus proteiner för att studera om de befann sig på samma 
ställe som virus RNA:t i cellen.  
Vi har även studerat hur viruset skulle kunna påverka stabiliteten mellan celler, 
vilket skulle kunna orsaka t.ex de inre blödningar som ses i patienter. Det har vi 
gjort genom att odla ut epitelceller på ett membran tills de var täta och 
polariserade, dvs. har en övre och en undre sida som delvis är olika. Sedan 
infekterade vi epitelcellerna med virus för att se om det räckte med bara virus 
infektion för att cellerna skulle förlora sin täthet. Vi kom fram till bara virus 
infektion inte var tillräckligt utan troligen måste människans immunförsvar också 
vara med och påverka. Därför infekterade vi även en speciell typ av immunceller, 
dendritiska celler, med CCHFV. Dendritiska celler har en viktig roll i 
immunförsvaret och kan både utsöndra cytokiner, vilket kan påverka andra celler 
att gå i försvarsställning och även presentera en bit av viruset för en T cell så att 
den aktiveras, och tillverkar antikroppar mot just det viruset.  När vi tillsatte 
CCHFV infekterade dendritiska celler till våra polariserade epitelceller så 
påverkade det inte heller stabiliteten mellan cellerna. Vi såg dock att viruset nu 
hade mycket lättare att ta sig in från den övre sidan än den undre. Det är motsatsen 
till det vi såg när vi bara tillsatte virus och vi spekulerar om den denritiska cellen 
utsöndrar något som hjälper viruset att ta sig in från den övre sidan av 
epitelcellerna. Exakt vad det skulle kunna vara är i dagsläget oklart. 
Antalet fall av Krim-Kongo blödarfeber har de senaste åren ökat och viruset har 
även hittats på nya geografiska plaster. Med tanke på de svåra symtom som 
sjukdomen kan ge och att det idag inte finns någon specifik behandling är det 
därför viktigt att öka kunskapen om detta virus. Något som denna avhandling har 
gjort. 
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